CVS Health Co. (NYSE:CVS) Shares Sold by Beddow Capital Management Inc.

Beddow Capital Management Inc. lowered its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 15.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 40,260 shares of the pharmacy operator's stock after selling 7,250 shares during the quarter. Beddow Capital Management Inc.'s holdings in CVS Health were worth $1,807,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Legacy Investment Solutions LLC purchased a new stake in CVS Health in the third quarter worth $31,000. Ridgewood Investments LLC increased its stake in CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock worth $28,000 after buying an additional 450 shares during the period. Stonebridge Financial Group LLC purchased a new stake in CVS Health in the 4th quarter valued at about $28,000. RPg Family Wealth Advisory LLC purchased a new position in shares of CVS Health during the third quarter worth approximately $40,000. Finally, Hopwood Financial Services Inc. bought a new stake in shares of CVS Health during the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

CVS stock traded up $0.68 during trading on Wednesday, reaching $67.16. The company had a trading volume of 6,992,507 shares, compared to its average volume of 11,079,778. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The firm has a 50-day simple moving average of $61.22 and a 200-day simple moving average of $57.46. The company has a market cap of $84.68 billion, a price-to-earnings ratio of 18.35, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $80.75.

Remove Ads

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, sell-side analysts expect that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date is Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is presently 72.68%.

Insider Activity at CVS Health

In related news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael F. Mahoney bought 30,000 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the transaction, the director now owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CVS shares. Truist Financial raised their price objective on CVS Health from $60.00 to $76.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Barclays lifted their price objective on CVS Health from $71.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. UBS Group dropped their target price on shares of CVS Health from $62.00 to $59.00 and set a "neutral" rating on the stock in a report on Tuesday, February 11th. Argus set a $77.00 price target on shares of CVS Health in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald raised shares of CVS Health from a "neutral" rating to an "overweight" rating in a report on Wednesday, February 12th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, CVS Health has an average rating of "Moderate Buy" and a consensus price target of $70.39.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.